Related Experiment Video
Updated: May 2, 2026

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024
Utility of gene expression profiling score variability to predict clinical events in heart transplant recipients
Mario C Deng1, Barbara Elashoff, Michael X Pham
11 University of California, Los Angeles, CA. 2 XDx Inc., Brisbane, CA. 3 Stanford University Medical Center, Stanford, CA. 4 VA Palo Alto Health Care System, Palo Alto, CA. 5 University of Pittsburgh Medical Center, Pittsburgh, PA. 6 Intermountain Medical Center and Intermountain Healthcare, Salt Lake City, UT. 7 Cleveland Clinic, Cleveland, OH. 8 Hospital of the University of Pennsylvania, Philadelphia, PA. 9 Mid America Heart Institute, Saint Luke's Hospital, Kansas City, MO. 10 University of Chicago Medical Center, Chicago, IL. 11 Northwestern University, Chicago, IL. 12 Washington University School of Medicine, St. Louis, MO. 13 Newark Beth Israel Medical Center, Newark, NJ. 14 Texas Heart Institute, Houston, TX. 15 Columbia University, New York City, NY. 16 Address correspondence to: Mario Deng, M.D., F.A.C.C., F.E.S.C., Advanced Heart Failure/Mechanical Support/Heart Transplant, David Geffen School of Medicine at UCLA, Ronald Reagan UCLA Medical Center, 100 Medical Plaza Drive, Suite 630 Los Angeles, CA 90095.
Background:
Gene expression profiling test scores have primarily been used to identify heart transplant recipients who have a low probability of rejection at the time of surveillance testing. We hypothesized that the variability of gene expression profiling test scores within a patient may predict risk of future events of allograft dysfunction or death.
Method:
Patients from the IMAGE study with rejection surveillance gene expression profiling tests performed at 1- to 6-month intervals were selected for this cohort study. Gene expression profiling score variability was defined as the standard deviation of an individual's cumulative test scores. Gene expression profiling ordinal score (range, 0-39), threshold score (binary value=1 if ordinal score ≥ 34), and score variability were studied in multivariate Cox regression models to predict future clinical events.
Results:
Race, age at time of transplantation, and time posttransplantation were significantly associated with future events in the univariate analysis. In the multivariate analyses, gene expression profiling score variability, but not ordinal scores or scores over threshold, was independently associated with future clinical events. The regression coefficient P values were <0.001, 0.46, and 0.773, for gene expression profiling variability, ordinal, and threshold scores, respectively. The hazard ratio for a 1 unit increase in variability was 1.76 (95% CI, 1.4-2.3).
Discussion:
The variability of a heart recipient's gene expression profiling test scores over time may provide prognostic utility. This information is independent of the probability of acute cellular rejection at the time of testing that is rendered from a single ordinal gene-expression profiling test score.
More Related Videos
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

